RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641

The outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem. Here, we aimed to understand how RCC cells acquire resistance to PI3K-mTOR inhibition. W...

Full description

Bibliographic Details
Main Authors: Earwa, P, Anderson, C, Willenbrock, F, Harris, A, Protheroe, A, Macaulay, V
Format: Journal article
Published: Public Library of Science 2018
_version_ 1797087803769618432
author Earwa, P
Anderson, C
Willenbrock, F
Harris, A
Protheroe, A
Macaulay, V
author_facet Earwa, P
Anderson, C
Willenbrock, F
Harris, A
Protheroe, A
Macaulay, V
author_sort Earwa, P
collection OXFORD
description The outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem. Here, we aimed to understand how RCC cells acquire resistance to PI3K-mTOR inhibition. We used the RCC4 cell line to generate a model of in vitro resistance by continuous culture in PI3K-mTOR kinase inhibitor NVP-BEZ235 (BEZ235, Dactolisib). Resistant cells were cross-resistant to mTOR inhibitor AZD2014. Sensitivity was regained after 4 months drug withdrawal, and resistance was partially suppressed by HDAC inhibition, supporting an epigenetic mechanism. BEZ235-resistant cells up-regulated and/or activated numerous proteins including MET, ABL, Notch, IGF-1R, INSR and MEK/ERK. However, resistance was not reversed by inhibiting or depleting these pathways, suggesting that many induced changes were passengers not drivers of resistance. BEZ235 blocked phosphorylation of mTOR targets S6 and 4E-BP1 in parental cells, but 4E-BP1 remained phosphorylated in resistant cells, suggesting BEZ235-refractory mTORC1 activity. Consistent with this, resistant cells over-expressed mTORC1 component RAPTOR at the mRNA and protein level. Furthermore, BEZ235 resistance was suppressed by RAPTOR depletion, or allosteric mTORC1 inhibitor rapamycin. These data reveal that RAPTOR up-regulation contributes to PI3K-mTOR inhibitor resistance, and suggest that RAPTOR expression should be included in the pharmacodynamic assessment of mTOR kinase inhibitor trials.
first_indexed 2024-03-07T02:40:53Z
format Journal article
id oxford-uuid:aa6974c7-dd39-4a72-ac7d-578784b41bf7
institution University of Oxford
last_indexed 2024-03-07T02:40:53Z
publishDate 2018
publisher Public Library of Science
record_format dspace
spelling oxford-uuid:aa6974c7-dd39-4a72-ac7d-578784b41bf72022-03-27T03:14:56ZRAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:aa6974c7-dd39-4a72-ac7d-578784b41bf7Symplectic Elements at OxfordPublic Library of Science2018Earwa, PAnderson, CWillenbrock, FHarris, AProtheroe, AMacaulay, VThe outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem. Here, we aimed to understand how RCC cells acquire resistance to PI3K-mTOR inhibition. We used the RCC4 cell line to generate a model of in vitro resistance by continuous culture in PI3K-mTOR kinase inhibitor NVP-BEZ235 (BEZ235, Dactolisib). Resistant cells were cross-resistant to mTOR inhibitor AZD2014. Sensitivity was regained after 4 months drug withdrawal, and resistance was partially suppressed by HDAC inhibition, supporting an epigenetic mechanism. BEZ235-resistant cells up-regulated and/or activated numerous proteins including MET, ABL, Notch, IGF-1R, INSR and MEK/ERK. However, resistance was not reversed by inhibiting or depleting these pathways, suggesting that many induced changes were passengers not drivers of resistance. BEZ235 blocked phosphorylation of mTOR targets S6 and 4E-BP1 in parental cells, but 4E-BP1 remained phosphorylated in resistant cells, suggesting BEZ235-refractory mTORC1 activity. Consistent with this, resistant cells over-expressed mTORC1 component RAPTOR at the mRNA and protein level. Furthermore, BEZ235 resistance was suppressed by RAPTOR depletion, or allosteric mTORC1 inhibitor rapamycin. These data reveal that RAPTOR up-regulation contributes to PI3K-mTOR inhibitor resistance, and suggest that RAPTOR expression should be included in the pharmacodynamic assessment of mTOR kinase inhibitor trials.
spellingShingle Earwa, P
Anderson, C
Willenbrock, F
Harris, A
Protheroe, A
Macaulay, V
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641
title RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641
title_full RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641
title_fullStr RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641
title_full_unstemmed RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641
title_short RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641
title_sort raptor up regulation contributes to resistance of renal cancer cells to pi3k mtor inhibition pone d 17 28641
work_keys_str_mv AT earwap raptorupregulationcontributestoresistanceofrenalcancercellstopi3kmtorinhibitionponed1728641
AT andersonc raptorupregulationcontributestoresistanceofrenalcancercellstopi3kmtorinhibitionponed1728641
AT willenbrockf raptorupregulationcontributestoresistanceofrenalcancercellstopi3kmtorinhibitionponed1728641
AT harrisa raptorupregulationcontributestoresistanceofrenalcancercellstopi3kmtorinhibitionponed1728641
AT protheroea raptorupregulationcontributestoresistanceofrenalcancercellstopi3kmtorinhibitionponed1728641
AT macaulayv raptorupregulationcontributestoresistanceofrenalcancercellstopi3kmtorinhibitionponed1728641